Chris Thomas

Chris’ experience encompasses a broad range of industries, including chemicals, industrial/manufacturing, media, IP/IT, consumer goods, pharmaceuticals, aviation, semiconductor, and financial services.  Prior to joining Weil, Chris trained in the London office of another US law firm, before spending over two years working on competition matters in their Brussels office.

Representative experience as part of a team, including prior to joining Weil, includes acting for:

• American Securities’ portfolio company Emerald Kalama Chemical in its sale to Lanxess
• Maxim Integrated in its sale to Analog Devices
• Advent International portfolio company Cobham Limited in the sale of its air-to-air refueling business to Eaton Aerospace
• Leading payments provider in securing informal clearance from the CMA relating to a strategic acquisition of a competitor
• Global pharmaceutical company in securing informal clearance from the CMA relating to a $1billion acquisition of a clinical-stage biopharmaceutical company
• Confidential mandate for the electronics division of a Korean headquartered multinational relating to a European Commission inquiry into possible infringements under Article 101 and 102 TFEU
• Confidential mandate for an industrial manufacturing client in relation to the pursuit of an abuse of dominance complaint against a rival manufacturer
• Confidential mandates for a US headquartered consumer electronics business relating to a number of early-stage investigations by the European Commission into alleged Article 102 infringements
• Advent International Corporation on merger control and foreign direct investment filings relating to a number of portfolio acquisitions
• Brookfield Asset Management in relation on merger control and foreign direct investment filings relating to a number of portfolio acquisitions
• Ontario Teachers’ Pension Plan on merger control filings relating to its acquisition of Logoplaste Group